An effective tumor vaccine against malignant melanoma: Irradiated autologous tumor cells admixed with MVE-2

International Journal of Molecular Medicine

Volumn 3, Issue 1, 1999, Pages 95-102

  Novakovic, Srdjan ^a   Ihan, Alojz ^b   Wraber, Branka ^b   Jezersek, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

B 16 melanoma; Biological therapy; Tumor prevention; Tumor vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOKINE; PYRAN COPOLYMER;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; C57BL MOUSE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; RADIATION EXPOSURE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CANCER VACCINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MELANOMA; MICE; MICE, INBRED C57BL; PYRAN COPOLYMER; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0032616213     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.1.95     Document Type: Article

References (44)

1. Hill RP and Tannock IF: Introduction: cancer as a cellular disease. In: The Basic Science of Oncoloey. Tannock IF and Hill RP (eds). Me Craw-Hill, New York, pp1-4, 1992.
2. Vieweg J, Boczkowski D, Roberson MK, Edwards WD, Philip M, Philip R, Rudoll T, Smith C, Robertson C and Gilboa E: Efficient gene transfer with adeno-associatcd virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55: 2366-2372, 1995.
3. Nakamura Y, Wakimoto H, Abe J, Kancgac Y, Saito I, Aoyagi M, Hirakawa K and Hamada H: Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interlcukin 2. Cancer Res 54: 5757-5760, 1994.
4. Tos GA, Cignetti A, Rovera G and Foa R: Retroviral vector-mediated transfer of the tumor necrosis factor u gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. Blood 87: 2486-2495, 1996.
5. Ehrkc MJ, Verstovsek S, Krawczyk MC, Ujhazy P, Zalcskis G, Maccubbin LD and Minich E: Cyclophosphamide plus tumor necrosis factor-α chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer 63: 463-471, 1995.
6. Kus B, Seraa G, Novakovic S, Urbani J and Stale A: Modification of TNF-α pharmacokinetics in SA-1 tumor-bearing mice. Int J Cancer 55: 110-114, 1993.
7. Novakovic S, Menart V, Gaberc-Porekar V, Stale A, Sersa G, Cemazar M and Jezersek B: New TNF-α analogues: a powerful but less toxic biological tool acainst tumors. Cytokine 8: 597-604, 1997.
8. Jezersek B, Novakovic S, Scrsa G, Auersperg M and Flcischmann WR Jr: Interactions of interfcron and vinblastine on experimental tumor model melanoma B-16 in vitro. Anticanccr Drugs 5: 53-56, 1994.
9. Novakovic S and Boldogh I: In vitro TNF-α production and in vivo alteration of TNF-α RNA in mouse peritoneal macrophages alter treatment with different bacterial derived aeents. Cancer Lett 81: 99-109, 1994.
10. Pardoll DM: Cancer vaccines. Trends Pharmacol Sci 14: 202-208, 1993.
11. Novakovic S: Current approaches to gene therapy in oncology: construction of tumor vaccines. Radiol Oncol 30: 260-267, 1996.
12. Kopf AW: Host defense acainst malignant melanoma. Hosp Prac 6: 116-119, 1971.
13. Cochran AJ and Hoon DB: Immunological aspects of malignant melanoma. In: Cutaneous Melanoma. Veroncsi U, Cascinclli N and Santinami M (eds). Academic Press, New York, pp47-61, 1987.
14. Boon T, Ccrottini J and van den Eyndc B: Tumor antigens rccosnizcd by T lymphocytes. Annu Rev Immunol 12: 337-365, 1994.
15. Tucker MA, Colcman CN and Cox RS: Risk of second cancers after treatment for Hodckin's disease. N Encl J Med 318: 76-81, 1988.
16. Ellias EG, Suter MC and Fabian SD: Adjuvant immunothcrapy in melanoma with irradiated autologous tumor cells and low dose cyclophoshamidc. J Surg Oncol 64: 17-22, 1997.
17. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Intcrleukin-2 gene transfer into tumor cells abrogates tumorisenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
18. Russell SJ, Ecclcs SA, Flemming CL, Johnson CA and Collinns MKL: Decreased tumorigenicity of a transpantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 47: 244-251, 1991.
19. Dranoff G, Jaffcc E, Lazenby A, Golumbek P, Levitsky II, Brosc K, Jackson V, Hamada H, Pardoll D and Mulligan CR: Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
20. Allione A, Consalvo M, Nanni P, Lollini LP, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo PM, Dellabona P, Hock H, Blankcnstein T, Rosenthal MF, Gansbacher B, Bosco CM, Musso T, Gusclla L and Forni G: Immunizing and curative potential of replicating and nonreplicating murine mammary adcnocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, 1L-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-intcrfcron gene or admixed with conventional adjuvants. Cancer Res 54: 6022-6026, 1994.
21. + T cells by B7-transfected melanoma cells. Science 259: 368-370, 1993.
22. Townsend SE, Su FW, Atherton JM and Allison JP: Specificity and longevity of antitumor immune response induced by B7-transfccrcd tumors. Cancer Res 54: 6477-6483, 1994.
23. Plaksin D, Porgador A, Vadai E, Feldman M, Schirrmacher V and Eisenbach L: Effective anti-melastatic melanoma vaccination with tumor cells transfccted with MHC genes and/or infected with newcastle disease virus (NDV). Int J Cancer 59: 796-801, 1994.
24. Drazan EK, Shen DX, Csete EM, Zhang WW, Roth AJ, Busuttil WR and Shaked A: In vivo adenoviral-mediated human p53 tumor suppressor cenc transfer and expression in rat liver after resection. Surgery 116: 197-204, 1994.
25. Roth AJ, Mukhopadhyay T, Zhang WW, Fujiwara T and Georges R: Gene replacement strategies for the prevention and therapy of cancer. In: The Internet Book of Gene Therapy/Cancer Therapeutics. Sobol ER and Scanion JK (eds). Appleton & Lanec. Stamford, pp229-233, 1995.
26. Moolten FL and Wells JM: Curability of tumors bearing herpes thymidine kinase cencs transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300, 1990.
27. Moolten FL: Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287, 1994.
28. Sobol ER and Scanlon JK (eds): The Internet Book of Gene Therapy/Cancer Therapeutics. Applcton & Lance, Stamford, 1995.
29. Budzynski W, Chirigos M and Gruys E: Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Immunol Immunothcr 24: 253-258, 1987.
30. Salup RR, Hcrberman RB, Chirigos MA, Back T and Wiltrout RH: Therapy of peritoneal murine cancer with biological response modifiers. J Immunopharmacol 7: 417-436, 1985.
31. Wallace PK and Morahan PS: Role of macrophages in the immunotherapy of Lewis lung peritoneal carcinomatosis. J LeukocBiol 56: 41-51, 1994.
32. Scaringi L, Tissi L, Cornacchione P, Rosati E, Campanelli C, von Hunolstein C, Orcfici G, Rossi P and Marconi P: Antibody-independent protection in mice against type la group B streptococcus lethal infection. FEMS Immunol Med Microbiol 9: 151-162, 1994.
33. Piccoli M, Saito T and Chirigos MA: Bimodal effects of MVE-2 on cytotoxic activity of natural killer cell and macrophage tumoricidal activities. Int J Immunopharmacol 6: 569-576, 1984.
34. Shlick E, Ruffmann R, Hartung K and Chirigos MA: Modulation of myelopoiesis by CSF or CSF-inducing biological response modifiers. J Immunopharmacol 7: 141-166, 1985.
35. Rios A, Roscnblum M, Powcll M and Mcrsh E: Phase I study of MVE-2 therapy in human cancer. Cancer Treat Rep 67: 239-243, 1983.
36. Morahan PS, Pinto A, Stcwart D, Murasco DM and Brinton MA: Varying role of alpha/beta intcrferon in the antiviral efficacy of synthetic immunomodulators against Scmliki Forrcst virus infection. Antiviral Res 15: 241-254, 1991.
37. Yamamoto H, Miki T, Oda T, Hirano T, Sera Y, Akagi M and Macda H: Reduced bone marrow toxicity of ncocarzinostatin by conjucation with divinyl clhcr-malcic acid copolymer. Eur J Cancer 26: 253-260, 1990.
38. Kancda Y, Yamamoto Y, Tsunoda S, Kamada H, Tsutsumi Y, Hirano T and Mayumi T: Bioconjugation of tumor necrosis factor-alpha with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency. Biochcm Biophys Res Commun 239: 160-165, 1997.
39. Blankenstein T, Qin Z, Überla K, Müller W, Rosen H, Volk DH and Diamanstein T: Tumor suppression after tumor cell-targeted tumor necrosis factor α ccne transfer. J Exp M cd 173: 1047-1052, 1991.
40. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 93: 10399-10404, 1996.
41. Guo YJ, Chc XY, Shcn F, Xie PT, Ma J, Wang NX, Wu GS, Anthony DD and Wu CM: Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispccific monoclonal antibodies. Nat Med 3: 451-455, 1997.
42. Kelso A: Cytokines: structure function and synthesis. Curr Opin Immunol 2: 215-225, 1989.
43. Borden EC and Sondcl PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65: 800-814, 1990.
44. Roscnberg SA, Lotzc MT and Mule JJ: New approaches to the immunotherapy of cancer. Ann Intern Med 108: 853-864, 1988.